Kelly E. McCann, MD, PhD

Dr. Neil Iyengar continues the discussion on HER2-positive early breast cancer by exploring how the DESTINY-Breast11 findings may translate into routine clinical practice.

Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer.

Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the need for breast cancer research that encompasses drugs with different payloads.

Kelly Elizabeth McCann, MD, PhD, discusses the TROP2-directed ADCs that are clinically available for metastatic TNBC management.

Kelly Elizabeth McCann, MD, PhD, discusses considerations for the sequential use of ADCs with similar payloads in HER2-positive metastatic breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the role of post-neoadjuvant T-DXd in HER2-positive breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer.

Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Looking ahead, the faculty discuss unanswered questions and future data needs in the adjuvant treatment of HR-positive, HER2-negative early breast cancer.

A second case highlights a postmenopausal patient with lower nodal burden but biologically high-risk HR-positive, HER2-negative breast cancer.

Strategies to improve tolerability and adherence to abemaciclib in the adjuvant setting are examined in detail.

Strategies to improve tolerability and adherence to abemaciclib in the adjuvant setting are examined in detail.

Treatment selection between abemaciclib and ribociclib is explored for a patient with extensive nodal involvement.

Using the same high-risk patient scenario, the discussion turns to practical strategies for sequencing adjuvant endocrine therapy, ovarian function suppression, and CDK4/6 inhibition.

A premenopausal patient with stage III, node-positive HR-positive, HER2-negative breast cancer is presented to illustrate real-world risk stratification.

Long-term follow-up from the monarchE and NATALEE trials continues to influence treatment decisions in HR-positive, HER2-negative early breast cancer.

Erica Mayer, MD, and Kelly McCann, MD, outline how clinicians define high-risk hormone receptor–positive, HER2-negative early breast cancer in contemporary practice.

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.